150 related articles for article (PubMed ID: 36372398)
21. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
[TBL] [Abstract][Full Text] [Related]
22. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
[TBL] [Abstract][Full Text] [Related]
23.
Piedimonte S; Power J; Foulkes WD; Weber E; Palma L; Schiavi A; Ambrosio E; Konci R; Gilbert L; Jardon K; Baret L; Zeng X
Int J Gynecol Cancer; 2020 Nov; 30(11):1757-1761. PubMed ID: 32759180
[TBL] [Abstract][Full Text] [Related]
24. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
[No Abstract] [Full Text] [Related]
25. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
[TBL] [Abstract][Full Text] [Related]
26. Ovarian cancer onset across different
Marchetti C; Ataseven B; Cassani C; Sassu CM; Congedo L; D'Indinosante M; Cappuccio S; Rhiem K; Hahnen E; Lucci Cordisco E; Arbustini E; Harter P; Minucci A; Scambia G; Fagotti A
Int J Gynecol Cancer; 2023 Feb; 33(2):257-262. PubMed ID: 36581488
[TBL] [Abstract][Full Text] [Related]
27. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
[TBL] [Abstract][Full Text] [Related]
28. Magnetic resonance imaging for distinguishing ovarian clear cell carcinoma from high-grade serous carcinoma.
Ma FH; Qiang JW; Zhang GF; Li HM; Cai SQ; Rao YM
J Ovarian Res; 2016 Jul; 9(1):40. PubMed ID: 27377917
[TBL] [Abstract][Full Text] [Related]
29. The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit.
Frugtniet B; Morgan S; Murray A; Palmer-Smith S; White R; Jones R; Hanna L; Fuller C; Hudson E; Mullard A; Quinton AE
BJOG; 2022 Feb; 129(3):433-442. PubMed ID: 34657373
[TBL] [Abstract][Full Text] [Related]
30. The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan.
Murakami W; Tozaki M; Nakamura S; Ide Y; Inuzuka M; Hirota Y; Murakami K; Takahama N; Ohgiya Y; Gokan T
Breast Cancer; 2019 Sep; 26(5):552-561. PubMed ID: 30820924
[TBL] [Abstract][Full Text] [Related]
31. MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma.
Li HM; Qiang JW; Xia GL; Zhao SH; Ma FH; Cai SQ; Feng F; Fu AY
J Ovarian Res; 2015 Apr; 8():26. PubMed ID: 25926038
[TBL] [Abstract][Full Text] [Related]
32. Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a Diagnosis of Epithelial Tubo-Ovarian Carcinoma.
Bernard J; Mehros W; Gregoire J; Douville P; Renaud MC; Sebastianelli A; Langlais EL; Plante M
J Obstet Gynaecol Can; 2022 Oct; 44(10):1047-1053. PubMed ID: 35779836
[TBL] [Abstract][Full Text] [Related]
33. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
34. Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status.
Corvigno S; Burks JK; Hu W; Zhong Y; Jennings NB; Fleming ND; Westin SN; Fellman B; Liu J; Sood AK
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3545-3555. PubMed ID: 34476576
[TBL] [Abstract][Full Text] [Related]
35. High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of
Stroot IAS; Brouwer J; Bart J; Hollema H; Stommel-Jenner DJ; Wagner MM; van Doorn HC; de Hullu JA; Gaarenstroom KN; Beurden M; van Lonkhuijzen LRCW; Slangen BFM; Zweemer RP; Gómez Garcia EB; Ausems MGEM; Boere IA; van Engelen K; van Asperen CJ; Schmidt MK; Wevers MR; de Bock GH; Mourits MJE;
J Clin Oncol; 2023 May; 41(14):2523-2535. PubMed ID: 36809028
[TBL] [Abstract][Full Text] [Related]
36. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
Soslow RA; Han G; Park KJ; Garg K; Olvera N; Spriggs DR; Kauff ND; Levine DA
Mod Pathol; 2012 Apr; 25(4):625-36. PubMed ID: 22193042
[TBL] [Abstract][Full Text] [Related]
37. Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes.
Hussein YR; Ducie JA; Arnold AG; Kauff ND; Vargas-Alvarez HA; Sala E; Levine DA; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):404-9. PubMed ID: 26574845
[TBL] [Abstract][Full Text] [Related]
38. BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
Eoh KJ; Park JS; Park HS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
Gynecol Oncol; 2017 Apr; 145(1):137-141. PubMed ID: 28159408
[TBL] [Abstract][Full Text] [Related]
39. Dynamic contrast-enhanced and diffusion-weighted MRI of invasive breast cancer for the prediction of sentinel lymph node status.
Choi EJ; Youk JH; Choi H; Song JS
J Magn Reson Imaging; 2020 Feb; 51(2):615-626. PubMed ID: 31313393
[TBL] [Abstract][Full Text] [Related]
40. Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland.
Pallonen TA; Lempiäinen SMM; Joutsiniemi TK; Aaltonen RI; Pohjola PE; Kankuri-Tammilehto MK
Sci Rep; 2022 Apr; 12(1):6704. PubMed ID: 35469032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]